In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriVascular's Sequel Could Be a Blockbuster

Executive Summary

When Boston Scientific shut down TriVascular all appeared to be lost for the one-time hard-charging start-up that took on the daunting abdominal aortic aneurysm market. But TriVascular’s core investors and evangelical executive team have given the company new life.
Advertisement

Related Content

Abingworth's Bet On Lombard: Best Of Both Worlds For VCs
EVAR Market: Challenges, Innovation and Growth
EVAR Market: Challenges, Innovation and Growth
Advancing The Technological Frontier In AAA Repair
Top Device Stories of 2010: A Look Back and a Glance Forward
Top Device Stories Of 2010: Waiting For The Other Shoes To Fall
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
In Search of the Perfect Aortic Endograft
Boston Scientific Shuffles and Sells in Bid to Right Ship
Staying the Course in Endovascular AAA Repair

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003485

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel